These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34513918)

  • 21. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
    Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
    J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
    Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
    Front Oncol; 2020; 10():586019. PubMed ID: 33425739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
    Chen Y; Guo Y; Chen H; Ma F
    Front Neurol; 2020; 11():573264. PubMed ID: 33329315
    [No Abstract]   [Full Text] [Related]  

  • 24. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas.
    Zeng A; Yin J; Wang Z; Zhang C; Li R; Zhang Z; Yan W; You Y
    Oncoimmunology; 2018; 7(12):e1510277. PubMed ID: 30524906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
    Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
    Front Oncol; 2019; 9():1433. PubMed ID: 31921684
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma.
    Ji X; Ding F; Gao J; Huang X; Liu W; Wang Y; Liu Q; Xin T
    Front Oncol; 2020; 10():573800. PubMed ID: 33194678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
    Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
    Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular and clinical characterization of Galectin-9 in glioma through 1,027 samples.
    Yuan F; Ming H; Wang Y; Yang Y; Yi L; Li T; Ma H; Tong L; Zhang L; Liu P; Li J; Lin Y; Yu S; Ren B; Yang X
    J Cell Physiol; 2020 May; 235(5):4326-4334. PubMed ID: 31609000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
    Liu S; Wang Z; Wang Y; Fan X; Zhang C; Ma W; Qiu X; Jiang T
    Oncoimmunology; 2018; 7(2):e1382792. PubMed ID: 29308304
    [No Abstract]   [Full Text] [Related]  

  • 33. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
    Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
    EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
    Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
    Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
    Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
    J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific clinical and immune features of CD68 in glioma via 1,024 samples.
    Wang L; Zhang C; Zhang Z; Han B; Shen Z; Li L; Liu S; Zhao X; Ye F; Zhang Y
    Cancer Manag Res; 2018; 10():6409-6419. PubMed ID: 30568502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
    Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
    Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
    [No Abstract]   [Full Text] [Related]  

  • 38. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
    Guan X; Luo L; Begum G; Kohanbash G; Song Q; Rao A; Amankulor N; Sun B; Sun D; Jia W
    J Exp Clin Cancer Res; 2018 Oct; 37(1):255. PubMed ID: 30333031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.
    Bockmayr M; Klauschen F; Maire CL; Rutkowski S; Westphal M; Lamszus K; Schüller U; Mohme M
    Cancer Immunol Res; 2019 Sep; 7(9):1401-1411. PubMed ID: 31266783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.